Big Pharma’s Unlikely Price Pledge Leader
Executive Summary
Allergan is taking a page from Big Pharma’s strategy two decades ago to fend off efforts at direct price regulation by pledging restraint on price increases. The differences in the pledge – and the image of the pledge maker – are instructive.
You may also be interested in...
Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions?
US Branded Drug Invoice Price Increases Moderate In 2016
Price increases before rebates and other concessions stayed below double digits in 2016, as manufacturers responded to public and political pressure on pricing practices, the QuintilesIMS annual drug spending report shows.
US Branded Drug Invoice Price Increases Moderate In 2016
Price increases before rebates and other concessions stayed below double digits in 2016, as manufacturers responded to public and political pressure on pricing practices, the QuintilesIMS annual drug spending report shows.